Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia
Tóm tắt
Từ khóa
Tài liệu tham khảo
Shtivelman E, Lifshitz B, Gale RP, Canaani E . Fused transcript of ABL and BCR genes in chronic myelogenous leukemia. Nature 1985; 315: 550–554.
Kantarjian H, Sawyers C, Hochlaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.
Casali M, Truglio F, Milone G, Di Raimondo F, Parinello G, Maserati E et al. Trisomy 8 in Philadelphia chromosome (Ph 1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia. Genes Chromosomes Cancer 1992; 4: 269–270.
Bilhou-Nabera C, Marit G, Devianne I, Viard F, Salzes S, Montastruc M et al. A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia. Genes Chromosomes Cancer 1993; 4: 255–256.
Ariyama T, Inazawa J, Uemura Y, Kakazu N, Maekawa T, Urase FK et al. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of α-interferon therapy for Ph positive chronic myelocytic leukemia. Cancer Genet Cytogenet 1995; 81: 20–23.
Ohtuska E, Kikuchi H, Abe Y, Moriyama K, Ohno E, Hirota K et al. Acute myeloblastic leukemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukemia with Philadelphia chromosome. Br J Haematol 1995; 90: 951–953.
Izumi T, Imagawa S, Hatatake H, Miura Y, Ariyama T, Inazawa J et al. Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Int J Hematol 1996; 64: 73–77.
Fayad L, Kantarjian H, O'Brien S, Seong D, Keating M, Talpaz M . Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997; 11: 767–771.
Marktel S, Bua M, Marin D, Chase A, Udom C, Armstrong L et al. Emergence of additional chromosomal abnormalities following treatment with STI571 (Imatinib Mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase. Blood 2001; 98: 617a (abstr.).
Gambarcoti-Passeri C, Giudici G, le Coutre P, Bungaro S, Pogliani EM, Kreuzer KA et al. Non random chromosomal abnormalities in Ph-negative bone marrow (BM) cells from CML patients achieving major cytogenetic response (MCR) with STI571 (GleevecTM). Blood 2001; 98: 257b (abstr.).
Meunier V, Giraudier S, Van den Akker J, Perot C, Jouault H, Caron-Servan B et al. Treatment with STI571 (Novartis) in chronic myeloid leukemia (CML): unexpected hematological findings in a series of 26 patients. Blood 2001; 98: 263b (abstr.).
Braziel R, Launder M, Druker B, Olson S, Magenis E, Mauro M et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months experience. Blood 2002; 100: 435–441.
Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K . Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390–1393.
Bumm T, Müller C, Al-Ali HF, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph-negative cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941–1949.
Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Goodman O et al. The emergence of Philadelphia chromosome (Ph) negative trisomy 8 cells in patients treated with imatinib mesylate: clinical evidence for a multistep pathogenesis. Blood 2002; 100: 2299 (abstr.).
Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A . Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. Leukemia 2003; 17: 465–467.
Schoch C, Haferlach T, Kern W, Schnittgers S, Berger U, Hehlmann R et al. Occurence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17: 461–463.
O'Dwyer M, Gatter K, Loriaux M, Druker B, Olson S, Magenis E et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481–487.
McMullin M, Humphreys M, Byrne J, Russel N, Cuthbert R, O'Dwyer M . Chromosomal abnormalities in Ph− cells of patients on imatinib. Blood 2003; 102: 2700–2701.
Medina J, Kantarajian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during Imatinib Mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98: 1905–1911.
Sehested J . A simple method for R-banding of human chromosomes, showing a pH-dependent connection between R and G bands. Humangentik 1975; 21: 55–58.
Wiktor A, Rybicki B, Prao Z, Shurafa M, Barthel B, Maeda K et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000; 27: 11–16.
Maserati E, Aprili F, Vinante F, Locatelli F, Amendola G, Zatterale A et al. Trisomy 8 in myelodysplasia and acute leukaemia is constitutional in 15–20% of cases. Genes Chromosomes Cancer 2002; 33: 93–97.
Chandley AC, Hargreave TB, Fletcher JM, Soos M, Axworthy D, Price WH . Trisomy 8. Report of a mosaic human male with near-normal phenotype and normal IQ, ascertained through infertility. Hum Genet 1980; 55: 31–38.
Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387: 516–519.
Kharbanda S, Pandey P, Jin S, Inoue S, Bharti A, Yuan ZM et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 1997; 386: 732–735.
Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997; 387: 520–523.
Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S et al. Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 1998; 273: 3799–3802.
Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B et al. Radiation-induced assembly of Rad21 and rad52 combination complex requires ATM and c-Abl. J Biol Chem 1999; 274: 12748–12752.
Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806–809.